Uttarakhand suspends licences of 14 Patanjali products

May 01, 2024 12:58
Uttarakhand suspends licences of 14 Patanjali products

(Image source from: Twitter)

Uttarakhand suspends licences of 14 Patanjali products:- On April 15, the Uttarakhand government made the decision to suspend the licenses of 14 Patanjali products. Additionally, a criminal complaint has been filed against Ramdev, Acharya Balkrishna, and Patanjali for violating the Drugs and Magic Remedies Act. The products affected by the license suspension include Swasari Gold, Swasari Vati, Bronchom, Swasari Pravahi, Swasari Avaleh, Mukta Vati Extra Power, Lipidom, Bp Grit, Madhugrit, Madhunashini Vati Extra Power, Livamrit Advance, Livogrit, Eyegrit Gold, and Patanjali Drishti Eye Drop. This action has taken place during an ongoing hearing in the Supreme Court regarding Ramdev and Balkrishna's non-compliance with court orders that prohibited Patanjali Ayurved from running misleading advertisements for health remedies. The Supreme Court is currently reviewing a plea from the Indian Medical Association (IMA) in 2022, which accuses Ramdev and Patanjali of engaging in a smear campaign against the Covid vaccination drive and modern medical practices. Just last month, the court had instructed Ramdev, Acharya Balakrishnan, and Patanjali Ayurved Ltd to publicly apologize for their failure to adhere to the court's orders on misleading advertisements.

Ramdev and Balkrishna have both presented an "unconditional and unqualified apology" to the Supreme Court for the Patanjali advertisements that made false claims about the curative powers of their products. However, the court questioned the sincerity of their apology and asked for a more visible apology. Patanjali has now issued a new public apology, with larger fonts, in newspapers, expressing their regret for not complying with the court's orders. This apology is made both by the individuals and on behalf of the company.

If you enjoyed this Post, Sign up for Newsletter

(And get daily dose of political, entertainment news straight to your inbox)

Rate This Article
(0 votes)